Termination of Registration of a Class of Security Under Section 12(b) (15-12b)
07 Fevereiro 2022 - 11:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
001-38318
Commission
File Number
Odonate Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
3 East 28th
Street, 10th Floor
New York, New York 10016
(332)206-0935
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Common Stock, $0.01 par value per share
(Title of each class of securities covered by this Form)
None
(Titles of all
other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an
X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend theduty to file reports:
|
|
|
Rule 12g-4(a)(1)
|
|
☒
|
Rule 12g-4(a)(2)
|
|
☐
|
Rule 12h-3(b)(1)(i)
|
|
☒
|
Rule 12h-3(b)(1)(ii)
|
|
☐
|
Rule 15d-6
|
|
☐
|
Rule 15d-22(b)
|
|
☐
|
Approximate number of holders of record as of the certification or notice date: 83
Pursuant to the requirements of the Securities Exchange Act of 1934, Odonate Therapeutics, Inc. has caused this certification/notice to
be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
Date:
|
|
February 7, 2022
|
|
By:
|
|
/s/ Michael Hearne
|
|
|
|
|
|
|
Michael Hearne
|
|
|
|
|
|
|
Chief Financial Officer
|
Odonate Therapeutics (NASDAQ:ODT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Odonate Therapeutics (NASDAQ:ODT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
Notícias em tempo-real sobre Odonate Therapeutics Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Odonate Therapeutics, Inc.